Rigel Pharmaceuticals Inc. (New)

RIGLNASDAQUSD
30.49 USD
0.00 (0.00%)🟢PRE MARKET (AS OF 07:43 PM EDT)
🟢Market: OPEN
Open?$30.24
High?$30.90
Low?$29.35
Prev. Close?$30.51
Volume?158.3K
Avg. Volume?324.0K
VWAP?$30.56
Rel. Volume?0.49x
Bid / Ask
Bid?$26.24 × 100
Ask?$34.84 × 100
Spread?$8.60
Midpoint?$30.54
Valuation & Ratios
Market Cap?563.8M
Shares Out?18.5M
Float?17.5M
Float %?97.3%
P/E Ratio?1.54
P/B Ratio?1.44
EPS?$19.86
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?2.42Strong
Quick Ratio?2.30Strong
Cash Ratio?0.41Low
Debt/Equity?0.13Low
ValuationATTRACTIVELY VALUED
Score
100/100
P/E?
1.5CHEAP
P/B?
1.44CHEAP
P/S?
1.92CHEAP
P/FCF?
7.5CHEAP
EV/EBITDA?
4.5CHEAP
EV/Sales?
1.96CHEAP
Returns & Efficiency
ROE?
93.8%STRONG
ROA?
71.5%STRONG
Cash Flow & Enterprise
FCF?$75.6M
Enterprise Value?$575.5M
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Employees
174
Market Cap
559.8M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2000-11-29
Address
611 GATEWAY BOULEVARD, SUITE 900
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-624-1100